Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335926 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL29652034 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL6842010 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL6337655 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL9120461 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL158053 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL306514 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL1603596 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL416659 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 | |
| SCHEMBL28535921 | 0.79 | KMT2A (0.43) | SMN1; SMN2KDM4EKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | claimed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | claimed |
| EP-1331225-A1 | Method of preparing enantiomerically-enriched tetrahydrobenzothiepine oxides | G.D. SEARLE & CO. (US) | 2003-07-30 | — | — | EP | claimed |
| EP-1042314-B1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | SEARLE & CO (US) | 2003-03-19 | — | — | EP | claimed |
| US-6369220-B1 | OXIDIZING AN ARYL-3-HYDROXYPROPYLSULFIDE; OXIDIZING 3-HYDROXY GROUP INTO ARYL-3-PROPANALSULFOXIDE; CYCLIZATION | G.D. SEARLE, LLC | 2002-04-09 | — | — | US | claimed |
| US-5426233-A | Contacting dihalophenone type compound with chiral hydroxylating compound at low temperature | SCHERING CORPORATION (US) | 1995-06-20 | — | — | US | claimed |
| WO-1992017433-A1 | PREPARATION OF CHIRAL HYDROXYKETONES | SCHERING CORPORATION (US) | 1992-10-15 | — | — | WO | claimed |
| EP-0506341-A1 | Preparation of chiral hydroxyketones | SCHERING CORPORATION (US) | 1992-09-30 | — | — | EP | claimed |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4349846-A1 | CHIMERIC NUCLEIC ACID OLIGOMER INCLUDING PHOSPHOROTHIOATE AND BORANOPHOSPHATE, AND METHOD FOR PRODUCING SAME | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-5362744-A | Treatnent of athrosclerosis, anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
| EP-0526033-A1 | Benzimidazoles | FISONS plc (GB) | 1993-02-03 | — | — | EP | disclosed |
| WO-1993001183-A1 | IMIDAZOLE DERIVATIVE AS ACAT INHIBITOR | RHONE-POULENC RORER LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| WO-1993001184-A1 | IMIDAZOLES INHIBITORS AS ACAT AND THROMBOXANE TXA2 | RHONE-POULENC RORER LIMITED (GB) | 1993-01-21 | — | — | WO | disclosed |
| WO-1992017433-A1 | PREPARATION OF CHIRAL HYDROXYKETONES | SCHERING CORPORATION (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0506341-A1 | Preparation of chiral hydroxyketones | SCHERING CORPORATION (US) | 1992-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | SMN1; SMN2 1081/4885KDM4E 2305/4885KMT2A 2270/4885 |
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | SMN1; SMN2 994/4885KDM4E 1240/4885KMT2A 3789/4885 |
| US-20250163056-A1 | NONMUSCLE MYOSIN II INHIBITORS | MYH2, MYO3B, MYO1B | SMN1; SMN2 842/4885KDM4E 3550/4885KMT2A 3765/4885 |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | SMN1; SMN2 994/4885KDM4E 1240/4885KMT2A 3789/4885 |
| US-12338240-B2 | Nonmuscle myosin ii inhibitors | MYH2, MYO3B, MYO1B | SMN1; SMN2 842/4885KDM4E 3550/4885KMT2A 3765/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | SMN1; SMN2 905/4885KDM4E 2334/4885KMT2A 2929/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | SMN1; SMN2 1081/4885KDM4E 2305/4885KMT2A 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.